RxDoctor Payments Data

Pam Sholar, MD

Hematology & Oncology · Statesville, NCNPI 1710961404

Payments from drug & device makers

$95in general payments, 2019–2025

Across 2 payments — averaging $47.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$83
  • Gilead$12

What the payments were for

  • Food & beverage$8387%
  • Education$1213%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis1$83
Gilead1$12

How this compares

$95 in reported general payments places this provider in the 5th percentile of 358 hematology & oncology providers in North Carolina.

See all hematology & oncology providers in North Carolina

Medicare billing

Part B allowed, 2024
$2,820,896
Medicare patients
312
Services billed
142,025

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide27$470,921
IbrancePalbociclib24$371,998
BrukinsaZanubrutinib18$243,471
KisqaliRibociclib Succinate16$205,245
CalquenceAcalabrutinib Maleate12$184,841
JakafiRuxolitinib Phosphate11$177,923
SprycelDasatinib21$163,721
PromactaEltrombopag Olamine17$120,887
EliquisApixaban145$108,760
Abiraterone Acetate28$44,723
Sunitinib Malate11$34,543
XareltoRivaroxaban14$19,255
Letrozole143$2,794
Danazol12$2,319
Potassium Chloride111$1,345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisKisqali, Promacta$83$326,13133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 358 hematology & oncology providers in North Carolina.

Other hematology & oncology in Statesville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →